We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bioprogress | BPRG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 50.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 50.00 | 50.00 |
| Top Posts |
|---|
Posted at 11/9/2007 10:06 by marick Question:-What is the market going to do over the next few weeks with MELDEX ? Will they reappraise the Company in light of the name change? Will the Company finally come out of the shadows of false dawns and deliver whatthe management say they are delivering? What is MELDEX ? A speciality Pharma that has morphed out of a technology supplier. IF the BRokers notes are to be beleived it is a cashflow positive, shortly to be profitable high growth company which has very little in the way of debt and a huge delivery pipeline going on for a number of years. IN itself it looks like a great business that in a short space of time could be fairly large. IT also has the albatross around its neck that it it owns some rather interesting technology that is seen as being destabilising to the pharma industry. The MELDEX is likely to have a number of new products including partner products which have been excluded from value calculations coming to market during the next three months. The current Analyst Frances Cloud has written numerous notes and revions and states the short term price as being 97p without any partner incomes. THe fact that the old contracts , all of them, have had to be renegotied over the past two years, and that the technologies have been enhanced, new revenue streams derived, acquisitions made, units integrated and products developed in line with the market need, seems to have left the market cold on the future of the old Company. IF in changing a name you can get someone to re-look at the firm and examine what they have and where it is going the vital disconnect between value and shareprice may welll be reinstigated. My own view is that the Speciality Pharma business is very good, and when the Menoflavon and Rocgel are pushed the sales will be very large on their own. The margin on products is predicted to be over the 50% barrier and it makes sense to distribute as much as possible ourselves, but on very large products go into partnership with those with deeper pockets to ensure a good rollout of product.Since the end of June the marketing operation on the OTC side has been beefed up with the addition of 60 or so individuals from the acquisition of Melbrosin. IF this OTC division gets stuck into selling our widened stable of products the future looks very bright indeed. The much vaunted TABWRAP and SCP deals that have been mooted for some time are due imminently, but in reality the partner deals will be the icing on a cake that has been made using our Speciality Pharma sales. Much has been said of possible up front payments for SCP and our Partner Tabwrap, milestone and development payments fron nRobe etc, but the pure mathematics of the equation lead me to think that the odd million or two in these will be dwarfed by the sheer size of the income streams from the Speciality Pharma business. FC has next years income down as over £50million, and I would be very surprised if that target number wasn't beaten by 30-90%. IF any income from our DDS was ignored and a comparison made with any other spec pharma business in the world, we are valued at a fraction of whatthey are and we have a larger pipeline. Our management need to convey to the City what they have actually acheived. The interims will show that they have done the end of the beginning in getting the business the right way up through to profitability with a full pipeline. They will have drawn a line under the days of old and willl push forward a business with expanding turnover and profitability. The destabilisations in the share price of the last 7 months have hurt a number of people, but at some stage I think soon the market willl be able to see exactly what I have seen for some time. I don't think for an instant that we willl have a smooth timeof it, but I have concluded that the market price is not connected in the short term to how the firm is, and that in the long term these two items must reconnect. Whether the reason for the disconnect has been due to a conceerted external source, world makes, suppression by MM's or the wrong expectations of some investors I could only speculate about. I do know though that the managemenbt are aware of the disconnect and I beleive they have a plan to reconnect the value and the shareprice. IF the name change is the first part of this what is the betting tha the other parts of this plan willl be delivered soon, and in a timescale as per the Company's habit of being far quicker than others predicted it could be done. I am happy with the Company, and think that we will have our reconnect this year. I don't know what steps the management have taken but assume that as it has now become a priority that the action willl be co-ordinated, swift and effective. Some have conjectured that this could be in the form of roadshows, appointing a new joint house broker, Director purchases, broadsheet coverage, etc. I hope that they have hit the nail on the head, and that as soon as the new name is visible tha they get the coverage to attract some new investors to augment the stale bulls in the stock. Caveat Emptor |
Posted at 10/9/2007 20:03 by poorold FB9,imho, it is a significant event for several reasons: 1) it would still represent between 5%-10% of net revenues for this year. That seems a significant enough size to trigger an RNS. 2) it would represent the first deal of it's kind and not already an ongoing revenue stream that investors expect. 3) it certainly meets the rule requiring an RNS in that should information be available to any party that might act upon it before that information is available to everyone...it needs to be RNS'd if there is a thought that it could affect the share price. and certainly a global pharma ordering a TabWrap System would materially impact many investors' views of the worth and potential of this company's share price. what do the other folks think? |
Posted at 10/9/2007 19:31 by fatboy9 poorold - you said "I would not be surprised at all to find out a TabWrap System has been purchased by a global pharma either. I heard earlier this year that the next machine built would likely go that route." - strangely enough, this is a topic of conversation that I have been having offboard with several other investors. My question to the other investors and to you also, is does RT even have to tell us about the TTP ordering the machines until such time as commercialisation of a product because up until this point it will not have a material impact on the BPRG share price if the TTP has very deep pockets and can afford to pay for x machines out of their petty cash. FB9 |
Posted at 10/9/2007 11:09 by daveperry RNS Number:5679DBioProgress PLC 10 September 2007 For Immediate Release 10 September 2007 BioProgress plc Notification of Shareholding London, UK, 10 September 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the specialty pharma and healthcare company, was notified on 10 September 2007 that Credit Agricole Cheuvreux International Ltd now has an interest in 7,710,679 shares of BioProgress Plc representing 4.00% of the issued share capital of the Company. - ENDS - For further information: BioProgress Plc + 44 (0) 20 7098 9881 Richard Trevillion, CEO Steve Martin, CDO Hiral Patel, CFO Buchanan Communications + 44 (0) 20 7466 5000 Rebecca Skye Dietrich Mark Court Top 10 Institutions Position Pos Change Barclays Global Investors (UK) Ltd. 10,577,770 333,608 Fidelity International Limited 7,902,143 -1,711,216 Credit Agricole Asset Management (UK) Ltd. 7,446,317 -1,300,953 Man Financial, Ltd. 6,606,591 909,777 Trevillion (Richard) 5,702,850 0 MF Global Securities Ltd. 5,520,509 0 James Brearley & Sons Ltd. 3,894,436 -62,484 Dalton Strategic Partnership, L.L.P. 3,570,506 2,801,506 Henderson Global Investors Ltd. 2,430,017 0 Sfarti (Jean-Francois) 1,826,464 -300,000 |
Posted at 08/9/2007 16:00 by scrappycat boobly, Thanks for your views. I accept some, but dispute others. You stated:-'It`s about an emerging patern of self interest : Huge salary , Massive options , Option Sales at a wholly inappropriate point in time , Replacement options post sale , Huge salary increase (To me it seems obvious why the `Hapless Alan Clarke` of the corrupt GH era was retained - and that raises other questions).etc ..' I agree, largely, with these comments. However, there is never an appropriate time for a Director to sell shares. As for his reasons, I am not in a position to judge his needs. Furthermore, the share price did not drop immediately following the announcement of his disposal. Each and every one of us who was holding at the time had the opportunity to sell at roughly the same price. Personally, I regret that I did not follow his lead, for I would now have significantly more. This game is easy with hindsight. As for his salary, I accept that, at this time it appears disproportionate. However, if his corporate decisions and actions over the last two years prove instrumental in persuading a TTP that to utilise Bio's technology is safe, and advantageous to them (and I am confident that he will), then I think his current salary is a bargain. You obviously feel somewhat differently. You then stated:- 'That against a background of declining value for shareholders then brings into focus: Less than clear understandable terminology , Flexible / moving timescales , Directional clarity , Massive issue of paper at (perhaps)over depressed prices , Operational competence , secrecy , stooges , and of course the primary reason for discontent , a share price that today does not reflect what most investors , the company brokers and indeed RT , see as fair value.' I will respobd to these individually:- 'Less than clear understandable terminology'. Maybe I am simplistic, but I have not found the RNSs that have been produced lacking in clarity. I do accept that confusion appears to have been generated with respect to the revised Business Plan. For me, it is now a two pronged attack, with increasing emphasis to be placed on Meldex developing and marketing its own products, coupled with partnership agreements for the near to middle term future (the latter having the potential for immense income generation). 'Flexible / moving timescales'. This applies to every Aim stock I invest in, or have invested in (and there have been many). It comes with the territory. Investors demand timescales (when will I be rich), and the company gives, what is presumably, its best estimate. All Aim companies do so but, almost invariably, the company, being a minnow, is not in a position to ensure that its estimates are adhered to. Also, as with the introduction of the anti fraud technology, things can change that require a revision of the proposed agreements. In RT's defence, I have to say that I cannot recall any RNS that has defibed a specific timescale, Even the 3/4 months relating to the SCP came from a Broker's estimate if my memory serves me correctly. ' Massive issue of paper at (perhaps)over depressed prices.' Disappointing I agree, but if the expansion was necessary to provide the necessary platform to persuade the TTPs to sign on the dotted line, then it is totally justified IMHO. ' Operational competence'. I am not qualified to comment on this, but if what has been done was necessary to achieve the desired end (ie, the provision of the aforementioned platform), then his competence will satisfy me. The bungled recruitment of an FD was however,somewhat disquieting. 'secrecy'. I sincerely congralulate RT and the board on this. That NDAs exist is surely not seriously questioned. If so, I would be extremely angry if the board jeopardised a potential agreement by acceeding to the demands of some shareholders for more specific information. A good name in business is hard to come by, a bad one is easy to achieve. That RT runs a tight ship is evident from the lack of leakage of information contained in RNSs. Long may this continue. 'stooges' ??????. Not sure what you are getting at. 'a share price that today does not reflect what most investors , the company brokers and indeed RT , see as fair value.' Dealt with previously IMHO. Apologies to all who find my posts boring. Like to voice my thoughts occasionally, and boobly's post deserved a response. I read those of the rest of you during the week. |
Posted at 26/8/2007 22:43 by baton I too thought it was an excellent reminder of what's just under the surface. Thanks for the effort you put into it Poorold.For those of us who have bee following this company very closely for several years, we are familiar with this information Poorold has posted. But this share needs more volume to increase its price to levels where it starts to reflect the true value of the company. Many holders have topped up so much that their funds are drying up and cannot keep on doing so. So new investors are needed. But to attract new investors there needs to be summaries such as posted by Poorold to get their attention. Look at the volume of RNS' out there to wade through. For new investors it cannot be easy, there is so much information in the RNS' written in a dry complex style that needs to be sifted in order to then start to piece it together in their head. Any new investor looking in with a view to buying shares in this company would be at least be spurred on to carry on their own research after reading Poorold's summary of RNS' I reckon. |
Posted at 24/8/2007 19:44 by shanksy1 Sounds like they are a 'few' years behind us....Strategic Review stage..!Phoqus Group plc: Fundraising at 50 pence per share raising £5.2 million West Malling, UK, 3 July 2007 Phoqus Group plc (AIM: PQS) ("Phoqus" or the "Company"), the oral drug delivery and development company, today announces a proposed fundraising to raise £5.0 million ($10.1 million) net of expenses by way of a Placing of new Ordinary Shares to UK institutional investors and a management subscription. The Placing is fully underwritten by the Company's nominated adviser, Nomura Code Securities Limited. The Fundraising is conditional, inter alia, on the approval of Shareholders. A circular convening an EGM of the Company, which is expected to take place on 26 July 2007, is being posted to Shareholders. Admission will be made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on the AIM market of the London Stock Exchange. It is expected that Admission will become effective and that dealings on the new Ordinary Shares will commence on 27 July 2007. Placing Highlights And Strategic Update Phoqus to raise approximately £5.0 million ($10.1 million) net of expenses by way of a conditional fundraising to certain new and existing Shareholders of 10,409,300 new Ordinary Shares at an issue price of 50 pence per new Ordinary Share The funds raised will be used to progress the in-house development of Chronocort, the Company's product for the treatment of congenital adrenal hyperplasia ("CAH") and adrenal insufficiency ("AI"), through pivotal Phase III clinical trials The funds will also be used to provide the Company with the financial resources to implement its new strategy of developing in-house novel therapeutic products targeting unmet medical needs using its proprietary delivery technologies Commenting on the proposed Placing, Dr. Richard Mason, Chief Executive of Phoqus, said: "We are delighted to have the on-going support of our strong list of existing investors and to welcome new very high quality investors to the Company. This fundraising will allow us to progress our first major in-house product opportunity, Chronocort, through its pivotal Phase III clinical trials. "Having conducted a strategic review, we have decided to focus the Company's strategy on the development of novel therapeutic products that meet real and significant unmet medical needs. Chronocort is an excellent example of our ability to do this, using our advanced drug delivery technologies to improve or change the way that drugs behave in the body. We look forward to using these technologies at Phoqus to generate a valuable new pipeline of products able to bring significant benefits to patients." Enquiries: Phoqus Group plc 01732 870227 Dr Richard Mason, CEO Financial Dynamics 020 7831 3113 David Yates/John Gilbert Nomura Code Securities Limited 020 7776 1200 Phil Walker |
Posted at 21/8/2007 19:55 by benville1 March 04"As I was walking down the stairs of the London Capital Club a guy in front turned round to me and said 'How the hell do you value that then?' I just said 'Well, that is the question!'. How do we value BioProgress though? It will be interesting to see how CS do in their forthcoming broker note. I walked with this young city whizz-kid for a bit and it was obvious he held retail investors in low esteem. 'It's the retail investors who are *uggering this up for everyone', I replied 'Have you seen the ADVFN bulletin board?'. He was annoyed with how retail investors are dictating the direction of the BioProgress share price as opposed to the city institutions, and complained that he cannot time buying the shares correctly so long as retail investors are errr...messing...around. However he did say that 'This will be £2 this time next year.' 'Only £2' I replied, 'I think it will be more like £3.' Maybe we'll have been taken over by this time next year...I hope not though, I quite look forward to next years meeting!! " |
Posted at 19/8/2007 04:19 by snipbits now theni have watched on the sidelines at the argument that has rumbled on the last few months about who is telling the truth on these bulletin boards. a couple of nights ago duggan went ballistic about nobody listening to what he says about underhand manipulation of your average punter on these boards. in one corner you have people such as dwall, spacecowboy, marick etc. these are people are invested to the tune of 100's of thousands(maybe millions) of shares in the company that have a regular dialogue with executive members of the board and have the financial clout to organise meetings with the ceo. no matter whether you feel the meetings/conversatio the ceo values their opinion so highly to speak to them about tactical company moves. whether you feel this is right or not isnt important in what i am trying to say here. just accept that this is what is happening(incidently this is what happen in every single one of our peer companies!) in the other corner you have the likes of duggan and the cronies that have banded around him. duggan is a known trader that sells in and out of numerous companies and who's thoughts on any one of these companies changes as regularly as the wind direction. to rubbish what a heavyweight investor says over a known trader is wrong. the new teir 1's motives are always to make money, as opposed to trading a position to make enough beer money for that evening. as a small time(relatively)igno i get the feeling the likes of duggan spout the vitriol for the simple reason that they like the audience, they like the idea they have sway over what you think, when in reality they do not have the clout or intelligence to organise a meeting with a company ceo and make their feelings known. it is always simpler to anonimously rubbish a companies actions rather than positively improve your own investment. for the record the famous big hitter meeting with members of the board also included a couple of average joe investors who had done the legwork and got themselves invited to put their point across. this is what i like about the management. if you are willing to put the time in to get a dialogue with the boss then maybe you could get invited to a meeting to air your views. or you could sit at your computer hour after hour grinding out negativity that is only going to hurt your average investor. to summarise, i do not agree with any bulletin board manipulation, but if it is going to happen then i will always sit in the camp that try to manipulate the share price up(because after all, i, like them have money invested here) rather than a bunch of traders who swing positive to negative as quickly as the ac supply to your house. you decide because the truth is out there! |
Posted at 16/8/2007 22:22 by waldron AIM stocks not yet informing investors 30 July 2007 Only a month from the deadline set by the regulator of the Alternative Investment Market, almost 300 companies (over 15% of those listed on AIM) have not yet lodged their financial information on a website accessible to investors. A service providing this access for all UK PLCs is being launched by EveryInvestor: fcreports.com. "Our new service, Free Company Reports & Accounts (FCReports), is designed as a one-stop shop where investors can obtain financial reports on all UK-listed companies", says Chris Gilchrist, editor-in-chief of EveryInvestor, "But many AIM-listed companies are being slow to comply with the new rule and we doubt whether all of them will meet the August deadline." The AIM rule (Rule 26) on publishing financial information online is far more detailed and prescriptive than the older rules applying to companies listed on the London Stock Exchange. "This is good news for investors, who can expect all AIM-listed companies to provide full financial information on the internet. But the LSE, as the regulator of AIM listings, may have to impose penalties on companies that are slow to comply," says Gilchrist. Companies whose shares are listed on the LSE itself already have to lodge financial statements on a publicly accessible website, but it was only in February 2007 that this requirement was added to the AIM rules. Recent research has shown that even LSE-listed companies' financial information can be hard for investors to find. FCReports makes life easier for investors and other company financial information users, by providing a simple electronic library of all UK-listed PLCs' latest financial statements in free-to-download form. Users will be able to download as many reports as they wish and can register to receive alerts when new reports from target companies become available. FCReports will add financial reports from the missing AIM-listed companies to its database as they become available. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
